文献速递银屑病与炎症性皮肤病

中重度银屑病患者整体评估数字评定量表的测量学特性

Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
PubMed 文献 · Br J Dermatol · 2023-01-01

基于SPEECH前瞻性多中心观察性登记研究759例中重度斑块状银屑病患者,评估11点患者整体评估数字评定量表(PtGA NRS)的心理测量学特性。结果显示PtGA NRS重测信度良好(ICC 0.79-0.83),与PASI、sPGA、DLQI等显著相关,具有已知组效度和反应性,最小重要差异为-3。

要点

  • PtGA NRS重测信度良好,组内相关系数范围0.79-0.83。
  • PtGA NRS与PASI、sPGA、DLQI等显著相关,聚合效度 supported。
  • PtGA NRS对治疗前后PASI和DLQI变化有反应性,最小重要差异为-3。

核心结论

  • PtGA NRS在中重度斑块状银屑病患者中显示出良好的信度、效度和反应性,在临床试验和日常实践中可行。

研究设计与样本

  • 数据来自SPEECH研究,为前瞻性、多中心、观察性登记研究,纳入759例中重度银屑病患者,评估生物制剂、传统系统治疗和光疗的比较有效性和安全性。

主要发现

  • PtGA NRS重测信度组内相关系数范围0.79-0.83,未观察到地板或天花板效应。
  • PtGA NRS与PASI、sPGA、体表面积、DLQI及医院焦虑抑郁量表显著相关。
  • PtGA NRS与PASI和DLQI「症状与感受」维度相关性相对较大(除基线外所有相关性≥0.4),支持聚合效度。
  • 存在银屑病关节炎或关节症状与PtGA NRS无显著关联。
  • 多变量回归分析中,基线PtGA NRS由年龄、皮损范围、皮损强度、患者症状与感受及对工作或学校的影响预测。

关键数值与推荐

  • 重测信度组内相关系数范围0.79-0.83。
  • 除基线外,PtGA NRS与PASI和DLQI「症状与感受」维度的所有相关性≥0.4。
  • 最小重要差异为-3。
  • 随访期间PtGA NRS绝对值≤2与PASI 90或PASI 90加DLQI 0/1一致。

临床怎么用

  • PtGA NRS可用于中重度斑块状银屑病临床试验和日常实践中评估患者整体疾病严重程度。
  • PtGA NRS绝对值≤2可作为最小疾病活动状态的参考指标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient global assessment (PtGA) has been recommended as one of the core domains in psoriasis clinical trials. Among multiple versions of PtGA, the single-question, 11-point PtGA numeric rating scale (NRS) remains to be validated in patients with plaque psoriasis. OBJECTIVES: To evaluate the psychometric characteristics of an 11-point PtGA NRS for disease severity in patients with moderate-to-severe plaque psoriasis. METHODS: Data were analysed from 759 patients with moderate-to-severe psoriasis in the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), a prospective, multicentre and observational registry assessing the comparative effectiveness and safety of biologics (adalimumab, ustekinumab, secukinumab or ixekizumab), conventional systemic therapies (acitretin or methotrexate) and phototherapy. RESULTS: The test-retest reliability of the PtGA NRS showed good agreement (intraclass correlation coefficient range 0.79-0.83). No floor or ceiling effects of PtGA NRS were observed. The PtGA NRS was significantly correlated with the Psoriasis Area and Severity Index (PASI), static Physician Global Assessment (sPGA), body surface area, Dermatology Quality of Life Index (DLQI) and Hospital Anxiety and Depression Scale. Relatively large correlations of PtGA NRS with PASI and the DLQI 'symptoms and feelings' domain (all correlations ≥ 0.4 except at baseline) supported convergent validity. The presence of psoriatic arthritis or joint symptoms had no significant association with the PtGA NRS. In multivariate regression analyses, the PtGA NRS at baseline was predicted by age, lesion extent, lesion intensity, patients' symptoms and feelings, and impact on work or school. The PtGA NRS displayed known-groups validity with the PASI, sPGA and DLQI score bands. The PtGA NRS was responsive to change in PASI and DLQI after treatment. Anchor- and distribution-based approaches supported -3 as the minimal important difference for PtGA NRS. An absolute PtGA NRS ≤ 2 during follow-up was concordant with the state of minimal disease activity based on a 90% reduction in PASI (PASI 90) or PASI 90 plus a DLQI of 0/1. Sensitivity analysis using subgroup comparison and multiple imputation model yielded consistent conclusions. CONCLUSIONS: The PtGA NRS showed good reliability, validity and responsiveness in patients with psoriasis, and was feasible in clinical trials and daily practice.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Yu N, Peng C, Zhou J, et al. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis. Br J Dermatol. 2023. PMID: 37310289. doi:10.1093/bjd/ljad188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。